Annual Operating Expenses
$50.69 M
+$104.00 K+0.21%
December 31, 2023
Summary
- As of February 8, 2025, VIRX annual total operating expenses is $50.69 million, with the most recent change of +$104.00 thousand (+0.21%) on December 31, 2023.
- During the last 3 years, VIRX annual operating expenses has risen by +$31.88 million (+169.43%).
- VIRX annual operating expenses is now at all-time high.
Performance
VIRX Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$10.19 M
+$596.00 K+6.22%
September 30, 2024
Summary
- As of February 8, 2025, VIRX quarterly total operating expenses is $10.19 million, with the most recent change of +$596.00 thousand (+6.22%) on September 30, 2024.
- Over the past year, VIRX quarterly operating expenses has dropped by -$3.38 million (-24.89%).
- VIRX quarterly operating expenses is now -43.66% below its all-time high of $18.08 million, reached on September 30, 2022.
Performance
VIRX Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
VIRX Operating Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +0.2% | -24.9% |
3 y3 years | +169.4% | -24.9% |
5 y5 years | +169.4% | -24.9% |
VIRX Operating Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +96.5% | -43.7% | +6.2% |
5 y | 5-year | at high | +169.4% | -43.7% | +280.7% |
alltime | all time | at high | +169.4% | -43.7% | +280.7% |
Viracta Therapeutics Operating Expenses History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $10.19 M(+6.2%) |
Jun 2024 | - | $9.59 M(-30.9%) |
Mar 2024 | - | $13.88 M(+2.3%) |
Dec 2023 | $50.69 M(+0.2%) | $13.56 M(+8.7%) |
Sep 2023 | - | $12.47 M(+0.2%) |
Jun 2023 | - | $12.45 M(+2.0%) |
Mar 2023 | - | $12.21 M(+5.5%) |
Dec 2022 | $50.59 M | $11.57 M(-36.0%) |
Sep 2022 | - | $18.08 M(+72.1%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2022 | - | $10.51 M(+0.7%) |
Mar 2022 | - | $10.43 M(-7.8%) |
Dec 2021 | $25.80 M(+37.1%) | $11.32 M(+4.8%) |
Sep 2021 | - | $10.80 M(+15.9%) |
Jun 2021 | - | $9.32 M(-265.3%) |
Mar 2021 | - | -$5.64 M(-192.0%) |
Dec 2020 | $18.82 M | $6.13 M(+53.5%) |
Sep 2020 | - | $3.99 M(-5.8%) |
Jun 2020 | - | $4.24 M(-4.9%) |
Mar 2020 | - | $4.46 M |
FAQ
- What is Viracta Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Viracta Therapeutics?
- What is Viracta Therapeutics annual operating expenses year-on-year change?
- What is Viracta Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Viracta Therapeutics?
- What is Viracta Therapeutics quarterly operating expenses year-on-year change?
What is Viracta Therapeutics annual total operating expenses?
The current annual operating expenses of VIRX is $50.69 M
What is the all time high annual operating expenses for Viracta Therapeutics?
Viracta Therapeutics all-time high annual total operating expenses is $50.69 M
What is Viracta Therapeutics annual operating expenses year-on-year change?
Over the past year, VIRX annual total operating expenses has changed by +$104.00 K (+0.21%)
What is Viracta Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of VIRX is $10.19 M
What is the all time high quarterly operating expenses for Viracta Therapeutics?
Viracta Therapeutics all-time high quarterly total operating expenses is $18.08 M
What is Viracta Therapeutics quarterly operating expenses year-on-year change?
Over the past year, VIRX quarterly total operating expenses has changed by -$3.38 M (-24.89%)